Neogen Chemicals, Balaji Amines jump up to 11% in trade

What drove the rally in both stocks

Shares of Neogen Chemicals Ltd and Balaji Amines Ltd rose sharply in Wednesday’s trade, supported by positive brokerage commentary and updates around the Additional Surveillance Measure (ASM) framework. Neogen Chemicals jumped as much as 10.88% to Rs 1,752.60. Balaji Amines climbed 7.44% to Rs 1,841.30. The moves came alongside different ASM status for the two stocks, which typically affects trading conditions such as surveillance intensity. SBICap Securities noted Neogen Chemicals was excluded from the ASM framework. Balaji Amines, in contrast, was included in the short-term ASM framework.

ASM framework updates and why traders track them

ASM is a surveillance mechanism used by exchanges to monitor stocks showing unusual price or volume behaviour. Being included can lead to tighter trading conditions and higher scrutiny. Exclusion is often interpreted as a reduction in near-term surveillance constraints, although it does not change company fundamentals. In this context, SBICap’s note that Neogen was excluded from ASM acted as a sentiment tailwind. Balaji’s inclusion did not prevent a rise, likely because attention shifted to earnings and brokerage estimate upgrades.

Neogen Chemicals: FY27 seen as a “transformational year”

Arihant Capital Markets said Neogen Chemicals reiterated FY27 as a transformational year, with commissioning of the Pakhajan electrolyte facility and a Dahej expansion expected to materially scale battery chemicals revenue. The brokerage expects Neogen’s battery materials revenue to exceed Rs 300 crore in FY27, largely weighted toward H2FY27. Arihant also flagged Neogen’s FY29 consolidated revenue potential at Rs 3,700-4,200 crore. The note linked this longer-term potential to domestic gigafactory opportunities and non-FEOC compliant electrolyte capabilities through Neogen’s partnership with Morita Chemical Industries.

Neogen’s recent earnings context: Q4 FY26 performance

Neogen also drew attention following its quarterly performance update. The stock rose 3.3% to Rs 1,720.46 after the company reported resilient operational performance in Q4 FY26 despite elevated input costs, Dahej transition-related expenses, and geopolitical supply chain disruptions. On a consolidated basis, net profit was reported at Rs 11.39 crore in Q4 FY26, up 23.67% year-on-year on an adjusted basis and 208.67% quarter-on-quarter. Revenue from operations rose 21.57% year-on-year to Rs 246.56 crore in Q4 FY26, and increased 12.06% quarter-on-quarter from Rs 220.02 crore. Management said strategic pass-through mechanisms remained in place to offset higher input costs.

Dahej fire incident and exceptional loss disclosure

The company had earlier reported an exceptional loss of Rs 14.08 crore in Q4 FY25 and FY25 following a fire incident at its Dahej SEZ facility, including its Multi-Purpose Plant (MPP3), tank farms and warehouse. This disclosure has remained a key part of the near-term narrative around costs, recovery, and plant transitions. Separately, the provided context also noted Neogen was proactively managing its financial health through a planned Rs 150 crore investment from the promoter group and anticipated significant insurance recoveries.

Neogen snapshot: prices, range and key ratios mentioned

The data provided also included price points and selected metrics tracked by market participants. Neogen’s 52-week high was stated as Rs 1,883 and 52-week low as Rs 966.7. Another datapoint in the input pegged the current share price at Rs 1,681.7, and another line referenced Rs 1,580.10 as the share price “as on 19th May 2026,” underscoring intraday and cross-source differences. The same dataset flagged 3-year revenue growth of 16.6622%, 3-year profit growth of 2.6781%, and 3-year ROE of 7.8642%. It also stated promoter pledging increased from 0% to 9.76% in one quarter, and that the stock was trading at a PE of 98.06.

Balaji Amines: estimate upgrades, margin reset and a lower stance

For Balaji Amines, Elara Securities raised FY27 and FY28E revenue estimates by 17% and 30% to Rs 1,840 crore and Rs 2,600 crore. Elara attributed the revision to improved visibility on di-methyl-ether (DME) commissioning, an acetonitrile (ACN) upgrade, n-methyl-morpholine (NMM), and Balaji Specialty’s (BSCL) EDA and cyanide/EDTA-based expansion projects. Elara also raised its FY27 and FY28E EBITDA estimates by 38-51% as it factored in higher DME realisation linked to commercial LPG substitution, improved product mix, and operating leverage from new capacities. The brokerage lifted EBITDA margin estimates by 316 bps and 310 bps to 20.8% for FY27E and 22.1% for FY28E. Despite these upgrades, Elara raised its target price to Rs 1,696 from Rs 1,339 but downgraded the stock to Reduce, saying the market price appeared to be pricing in execution ahead of delivery.

Balaji Amines: Q4 FY26 numbers and dividend recommendation

Separately, Balaji Amines shares were reported to have hit a 20% upper circuit on the BSE at Rs 1,622.55 per share, alongside a Sensex move of 0.64% to 75,089.90. The buying was linked to the company’s Q4 FY26 results. In Q4 FY26, Balaji Amines reported a 57.7% increase in net profit to Rs 632 crore compared with Rs 400.6 crore a year ago, as per the provided text. Revenue from operations stood at Rs 3,947.8 crore versus Rs 3,527.2 crore year-on-year, up 12%. Total income was Rs 4,025.2 crore versus Rs 3,607.5 crore, and total expenses were Rs 3,166.6 crore versus Rs 3,068.2 crore. The board recommended a final dividend of Rs 11 per equity share, representing 550% on a face value of Rs 2 per share, subject to shareholder approval at the AGM.

Key numbers at a glance

Market Impact

The session highlighted how surveillance labels, quarterly results, and forward estimates can interact to move prices quickly in small and mid-cap chemical names. Neogen’s move reflected both a trading catalyst (ASM exclusion) and an operational narrative focused on electrolytes and battery materials scaling. Balaji’s move combined an earnings and dividend trigger with upgraded medium-term estimates, even as one brokerage turned more cautious on valuation. The inputs also showed that different price prints can appear across sources and timestamps, which is common during volatile sessions and around results days.

Analysis: why the FY27-FY29 commentary matters

The common thread in the brokerage notes is capacity commissioning and product-mix shift. For Neogen, Pakhajan and Dahej are positioned as key levers for battery chemicals, with the FY27 weighting skewed to the second half. The FY29 revenue potential range of Rs 3,700-4,200 crore, as cited by Arihant, sets a longer runway that investors will likely compare against quarterly execution and plant ramp-up milestones. For Balaji, Elara’s revisions link to specific projects (DME, ACN, NMM and BSCL expansions) and to a margin uplift through operating leverage and mix, but the Reduce rating signals that upgraded numbers do not automatically translate into a higher recommended stance at elevated prices.

Conclusion

Neogen Chemicals and Balaji Amines moved sharply as ASM updates, earnings signals, and refreshed brokerage models reshaped near-term sentiment. Next catalysts cited in the input remain tied to commissioning timelines, ramp-ups, and delivery against FY27-FY29 targets and margin assumptions, along with shareholder approval for Balaji’s final dividend.